Strategic partnership expands capabilities across GLP-1 and oligonucleotide therapeutics, creating a scalable platform for the development and delivery of complex medicines worldwide.
Zug, Switzerland, 26 October 2026 – Adalvo today announced a strategic partnership with Sinopep-Allsino Biopharmaceutical, a global leader in the development and manufacturing of complex pharmaceutical modalities, focused on the development and commercialisation of peptide and oligonucleotide products worldwide.
The collaboration combines Sinopep's scientific, development and manufacturing expertise with Adalvo's extensive commercial, regulatory and market access capabilities across more than 160 markets and a network of over 260 commercial partners. Together, the companies aim to accelerate the development and global delivery of high-value therapies across some of the pharmaceutical industry's fastest-growing and most innovative therapeutic segments.
Founded in 2009, Sinopep has established itself as a trusted development and manufacturing partner, supporting global pharmaceutical companies through its capabilities in complex peptides, oligonucleotides and advanced pharmaceutical technologies. The company's commitment to quality, technical excellence and scale has positioned it as a key contributor within the global advanced therapeutics ecosystem.
The partnership is designed as a long-term platform rather than a single-product collaboration, built on shared infrastructure, coordinated development pathways and scalable supply capabilities across multiple programmes. By combining complementary strengths, Adalvo and Sinopep intend to create a streamlined pathway from development through to commercialisation for a portfolio of complex therapies.
Under the agreement, Sinopep will serve as the development and manufacturing partner, supporting programmes from early-stage development through to commercial supply. Adalvo will lead global commercial strategy, regulatory navigation and partner engagement, leveraging its international platform to maximise the reach and value of each programme.
Peptide therapeutics, including GLP-1 receptor agonists, continue to transform the treatment of cardiometabolic diseases, while oligonucleotide therapeutics are emerging as one of the most promising advanced modalities in modern medicine, offering highly targeted approaches across a growing range of therapeutic areas. Together, these segments represent significant long-term growth opportunities within the global pharmaceutical market.
"Our partnership with Sinopep reflects a shared vision for the future of complex medicines. Sinopep's vertically integrated capabilities across development, manufacturing and commercial supply, combined with Adalvo's global commercial, regulatory and market access platform, create a powerful pathway to accelerate the development and delivery of peptide and oligonucleotide therapies worldwide. Together, we are building a scalable platform designed to create value across multiple programmes, markets and therapeutic areas."
“I believe both companies enjoy different areas of strength and expertise, hence complementary to each other for true win-win arrangements. Let’s believe in the growth brought by new products and new modalities of business development is infinite.”
This partnership forms part of Adalvo's broader strategy to expand its presence in advanced pharmaceutical modalities and reinforces its commitment to building scalable, long-term platforms across high-growth, complex therapeutic categories. By bringing together development excellence, manufacturing strength and global commercial reach, Adalvo and Sinopep are establishing a foundation for sustainable growth and future innovation.
About Sinopep
Sinopep-Allsino Biopharmaceutical Co., Ltd. is a leading worldwide commercial API supplier and full-service CDMO, delivering large-scale GMP manufacturing for peptides, oligonucleotides, and small molecules to support global biopharma partners from development through commercial supply. We provide established peptide capacity of multi-metric tons annually, proven commercial-scale production for small molecule generics and NCEs, and our new large-scale GMP oligonucleotide facility in Jiangsu Lianyungang capable of thousands of kilograms per year, including ASOs, siRNA, and advanced conjugates. With FDA-inspected facilities, strong regulatory expertise, and seamless end-to-end capabilities, Sinopep ensures reliable, high-quality, and cost-effective commercial API supply for innovative therapeutics worldwide.
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.